MA31767B1 - Composes organiques et leurs utilisations - Google Patents

Composes organiques et leurs utilisations

Info

Publication number
MA31767B1
MA31767B1 MA32757A MA32757A MA31767B1 MA 31767 B1 MA31767 B1 MA 31767B1 MA 32757 A MA32757 A MA 32757A MA 32757 A MA32757 A MA 32757A MA 31767 B1 MA31767 B1 MA 31767B1
Authority
MA
Morocco
Prior art keywords
organic compounds
amelioration
prevention
useful
treatment
Prior art date
Application number
MA32757A
Other languages
Arabic (ar)
English (en)
Inventor
Shawn D Britt
Lech Andrzej Ciszewski
Jiping Fu
Subramanian Karur
Yugang Liu
David Thomas Parker
Mahavir Prashad
Prakash Raman
Mohindra Seepersaud
Rui Zheng
Peichao Lu
Pascal Rigollier
Aregahegn Yifru
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31767B1 publication Critical patent/MA31767B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention décrit des composés organiques qui sont utiles pour le traitement, la prévention et/ou l'amélioration de maladies humaines.
MA32757A 2007-10-10 2010-04-08 Composes organiques et leurs utilisations MA31767B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97897407P 2007-10-10 2007-10-10
PCT/EP2008/063460 WO2009047264A1 (fr) 2007-10-10 2008-10-08 Composés organiques et leurs utilisations

Publications (1)

Publication Number Publication Date
MA31767B1 true MA31767B1 (fr) 2010-10-01

Family

ID=40243948

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32757A MA31767B1 (fr) 2007-10-10 2010-04-08 Composes organiques et leurs utilisations

Country Status (20)

Country Link
US (2) US8008263B2 (fr)
EP (1) EP2205584A1 (fr)
JP (1) JP5095824B2 (fr)
KR (2) KR101396696B1 (fr)
CN (2) CN101868452B (fr)
AR (1) AR068756A1 (fr)
AU (1) AU2008309589B2 (fr)
BR (1) BRPI0817881A2 (fr)
CA (1) CA2702132A1 (fr)
CL (1) CL2008002995A1 (fr)
CO (1) CO6270317A2 (fr)
CR (1) CR11310A (fr)
EA (1) EA020951B1 (fr)
MA (1) MA31767B1 (fr)
MX (1) MX2010003916A (fr)
PE (1) PE20091237A1 (fr)
TN (1) TN2010000137A1 (fr)
TW (1) TW200932737A (fr)
WO (1) WO2009047264A1 (fr)
ZA (1) ZA201001585B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2518079A3 (fr) * 2006-04-11 2012-12-12 Novartis AG Inhibiteurs du VHC/VIH et leur utilisation
WO2009082697A1 (fr) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Inhibiteurs de hcv protéase et leurs utilisations
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
CN104557880A (zh) 2007-12-21 2015-04-29 阿维拉制药公司 Hcv蛋白酶抑制剂和其用途
WO2010045266A1 (fr) * 2008-10-15 2010-04-22 Intermune, Inc. Peptides antiviraux therapeutiques
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CN105001302A (zh) * 2009-09-28 2015-10-28 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
TW201116540A (en) * 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
CN103179966B (zh) * 2010-10-08 2017-03-15 诺瓦提斯公司 磺酰胺ns3抑制剂的维生素e制剂
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013030750A1 (fr) 2011-09-01 2013-03-07 Lupin Limited Composés antiviraux
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
CN103420991B (zh) * 2012-05-17 2017-07-07 乳源东阳光药业有限公司 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用
TW201408669A (zh) * 2012-08-08 2014-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
TW201412709A (zh) 2012-09-28 2014-04-01 Sunshine Lake Pharma Co Ltd 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2014071007A1 (fr) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2914613B1 (fr) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (fr) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
CN103848819B (zh) * 2012-11-29 2017-04-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们在药物中的应用
US9416139B2 (en) 2012-11-29 2016-08-16 Sunshine Lake Pharma Co., Ltd. Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
WO2014082380A1 (fr) 2012-11-29 2014-06-05 Sunshine Lake Pharma Co., Ltd. Composés de type noyaux fusionnés utilisables en tant qu'inhibiteurs du virus de l'hépatite c, compositions pharmaceutiques en contenant et leurs utilisations
EP2964664B1 (fr) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
HK1220626A1 (zh) 2013-03-15 2017-05-12 The Centre For Drug Research And Development 具细胞毒性和抗有丝分裂的化合物以及其使用方法
MX2016008448A (es) 2013-12-27 2017-01-09 Zymeworks Inc Conjugados de var2csa-farmaco.
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
WO2015110048A1 (fr) 2014-01-23 2015-07-30 Sunshine Lake Pharma Co., Ltd. Composés cycliques pontés comme inhibiteurs du virus de l'hépatite c, compositions pharmaceutiques et utilisations correspondantes
ES2905569T3 (es) 2014-09-17 2022-04-11 Zymeworks Inc Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
CN111433210A (zh) 2017-12-20 2020-07-17 诺华股份有限公司 作为抗病毒药的稠合三环吡唑并-二氢吡嗪基-吡啶酮化合物
WO2022109360A1 (fr) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux dérivés de spiropyrrolidine
US12540141B2 (en) 2020-11-23 2026-02-03 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2022140515A1 (fr) * 2020-12-22 2022-06-30 The Regents Of The University Of California Nouveaux inhibiteurs spécifiques de cyp3a4 et leurs procédés d'utilisation
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US12643905B2 (en) 2021-07-23 2026-06-02 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023003610A1 (fr) * 2021-07-23 2023-01-26 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux dérivés de spiropyrrolidine
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023086400A1 (fr) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux dérivés de spiropyrrolidine
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
WO2023086352A1 (fr) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux dérivés de spiropyrrolidine
WO2023107417A1 (fr) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Agents antiviraux hétérocycliques
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
US12145942B2 (en) 2022-04-05 2024-11-19 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7012066B2 (en) * 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
MXPA04007163A (es) 2002-01-23 2004-10-29 Schering Corp Compuestos de prolina como inhibidores de la proteasa serina ns3 para utilizarse en el tratamiento de la infeccion por el virus de la hepatitis c.
JP4825129B2 (ja) * 2003-06-17 2011-11-30 シェーリング コーポレイション （１ｒ，２ｓ，５ｓ）−６，６−ジメチル−３−アザビシクロ［３，１，０］ヘキサン−２−カルボキシレートまたはその塩の調製のためのプロセスおよび中間体
MXPA06002250A (es) * 2003-08-26 2006-05-17 Schering Corp Inhibidores peptidomimeticos novedosos de la serina proteasa ns3 del virus de la hepatitis c.
MY148123A (en) * 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP1664091A1 (fr) * 2003-09-18 2006-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
CN1893978A (zh) * 2003-10-27 2007-01-10 沃泰克斯药物股份有限公司 用于hcv治疗的组合
KR20060118532A (ko) * 2003-12-11 2006-11-23 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ３／ｎｓ４ａ 세린 프로테아제의억제제
EP1711515A2 (fr) * 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
ATE438622T1 (de) * 2004-02-27 2009-08-15 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
US7173057B2 (en) * 2004-02-27 2007-02-06 Schering Corporation Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus
RU2428428C9 (ru) * 2004-02-27 2012-03-10 Шеринг Корпорейшн Серусодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
CN1950393A (zh) * 2004-02-27 2007-04-18 先灵公司 丙型肝炎病毒ns3蛋白酶的抑制剂
US7635694B2 (en) * 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
RU2006134005A (ru) * 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
WO2005107745A1 (fr) * 2004-05-06 2005-11-17 Schering Corporation Inhibiteur de l'hepatite c
WO2005123076A2 (fr) * 2004-06-08 2005-12-29 Vertex Pharmaceuticals, Inc. Compositions pharmaceutiques
MX2007002371A (es) * 2004-08-27 2007-04-23 Schering Corp Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
WO2006034337A2 (fr) * 2004-09-23 2006-03-30 Wyeth Derives de carbazole et de cyclopentaindole destines a traiter une infection par le virus de l'hepatite c
US20080267915A1 (en) * 2004-10-01 2008-10-30 Vertex Pharmaceuticals Hcv Ns3-Ns4a Protease Inhibition
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
US20060281689A1 (en) * 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US20070021351A1 (en) * 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US8119602B2 (en) * 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
WO2006130666A2 (fr) * 2005-06-02 2006-12-07 Schering Corporation Medicaments et procedes destines a combiner un inhibiteur de protease hcv et un competiteur akr
US20070004635A1 (en) * 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
ES2401661T3 (es) * 2005-08-02 2013-04-23 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
JP2009536158A (ja) * 2006-04-11 2009-10-08 ノバルティス アクチエンゲゼルシャフト Ｈｃｖ阻害剤
WO2007121124A2 (fr) * 2006-04-11 2007-10-25 Novartis Ag Composés organiques et leurs utilisations
WO2007120595A2 (fr) * 2006-04-11 2007-10-25 Novartis Ag Composés organiques et leurs utilisations
EP2518079A3 (fr) * 2006-04-11 2012-12-12 Novartis AG Inhibiteurs du VHC/VIH et leur utilisation
WO2008059367A1 (fr) 2006-11-14 2008-05-22 Pfizer Products Inc. Promédicaments de sulopénème
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルｇｐｒ４０調節因子
CL2008002998A1 (es) 2007-10-10 2009-11-20 Takeda Pharmaceuticals Co Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
UA100527C2 (en) 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators

Also Published As

Publication number Publication date
PE20091237A1 (es) 2009-09-14
BRPI0817881A2 (pt) 2015-03-31
CL2008002995A1 (es) 2009-06-26
EA201000556A1 (ru) 2010-10-29
KR101218882B1 (ko) 2013-01-07
AU2008309589B2 (en) 2012-07-05
EP2205584A1 (fr) 2010-07-14
US8008263B2 (en) 2011-08-30
JP2011500528A (ja) 2011-01-06
MX2010003916A (es) 2010-05-05
US20090137495A1 (en) 2009-05-28
CN101868452A (zh) 2010-10-20
KR20120094049A (ko) 2012-08-23
WO2009047264A1 (fr) 2009-04-16
CN104016970A (zh) 2014-09-03
ZA201001585B (en) 2010-12-29
US20110275819A1 (en) 2011-11-10
AU2008309589A1 (en) 2009-04-16
CO6270317A2 (es) 2011-04-20
KR101396696B1 (ko) 2014-05-16
CR11310A (es) 2010-05-06
TN2010000137A1 (en) 2011-09-26
AR068756A1 (es) 2009-12-02
JP5095824B2 (ja) 2012-12-12
EA020951B1 (ru) 2015-03-31
KR20100051749A (ko) 2010-05-17
US8222425B2 (en) 2012-07-17
CN101868452B (zh) 2014-08-06
TW200932737A (en) 2009-08-01
CA2702132A1 (fr) 2009-04-16

Similar Documents

Publication Publication Date Title
MA33155B1 (fr) Composes organiques et leurs utilisations
MA30392B1 (fr) Composes organiques et leurs utilisations
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MA30340B1 (fr) Nouveaux composes
MA30485B1 (fr) Aminothiazoles et leurs utilisations
TW200612926A (en) Compounds and compositions as ppar modulators
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
DE602007008434D1 (de) Rezeptoren
EP1606286A4 (fr) Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
WO2007022470A3 (fr) Methodes et compositions pour le traitement de maladies neurologiques
MX2010003916A (es) Espiro-pirrolidinas y su uso contra infeccion por el virus de hepatitis c (hcv) y por el virus de inmunodeficiencia humana (vih).
EP2010179A4 (fr) 4-carboxamides d'imidazoles substitués utilisés comme modulateurs des récepteurs de la cholécystokinine-1
TW200602330A (en) Compounds and compositions as PPAR modulators
MA30903B1 (fr) Derives de 2 - phenyl-6-minocarbonyl-pyrimidine
MA33753B1 (fr) Nouveaux camphènes arylés, procédés de préparation et utilisations de ceux-ci
TW200600505A (en) Compounds and compositions as ppar modulators